ELTP Discussion Topics 08/16/2014 10:28:41 $ELTP Here's

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
ELTP Discussion Topics 08/16/2014 10:28:41 $ELTP
Here's what people need to know when it comes to investing:


-Hindsight is 20/20.

-Long term investors ALWAYS outperform traders.

-Traders ALWAYS lose.

-The greatest investor of ALL TIME follows the long term approach.


Have a great day everyone.
The biggest Flip Flop statement ever for a Flipper!!! Lol
No it's completely UN-predictable.

HINDSIGHT IS 20/20.

I've followed this message board for over 3 years and read every message and EVERYONE HAS BEEN COMPLETELY WRONG ABOUT EVERYTHING


Bad idea to buy, hold, accumulate if you are in penny stocks; good way of going broke. Good idea to flip ELTP because it really is so predictable.
Bad idea.

It's a proven fact you make more money by never selling.

Ask Warren Buffett - The greatest investor of all time.

Also, it's a proven fact that all females outperform all males when it comes to investing. WHY? - Because THEY NEVER SELL!!!!!!!!!

This is why I will never sell and is why I currently have and will continue to make more money than everyone on this board who trades!!!!!!!!!

It's a proven fact that traders underperform the market and underperform ELTP.

All who have tried to trade stocks ALWAYS GET BURNED.

Warren Buffett - "Our favorite holding period is FOREVER".
Hmmmmmmmm!!!!!!! It has been reloading time and now it is time to actively wait for flipping opportunity creation and the ceremonious dumping of shares in the rinse repeat fashion. This has been the most consistent thing about ELTP over the past 3 years. I too am waiting to activate my FlipperMe alias.
Remember last year at the R and R conference Nasrat said "there are a lot of partners".

Here we are 1 YEAR LATER, STILL NO PARTNERS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Quote:
partnership talks underway

Why do you care if a run is coming????

You said you were a long term investor.
The question was not that Isradipine existed or didn't exist. It was that it should have launched by now and didn't courtesy of CEO who believes generics are bread crumbs but yet dumped 12 of the bread crumb producers on JT for a hefty $10M. No wonder CEO does his best to hype ELTP with his substantiated and undocumented protocols for evaluations, his own, and the mysterious evaluation company.

I do sense that hype is losing its edge; it is not producing like before. Wonder why? Could it be the millions upon millions of new shares in the A/S. I am told that there are 995,000,000 shares. Complicating this fact is the new "oh by the way" there is a 20,000sf addition in the pipeline that could cost millions more in shares. The irony is that Elite already has two facilities which were supposed to accommodate the ART; that 11 ANDA generics were farmed out to Epic. Incidentally the one not farmed out is the one that Elite said it couldn't produce then decided in could produce and hasn't produced to date.
Indeed good sir.....yes indeed Elite has come along way and the DD Longs saw what was coming from a long ways away and let no disturbance detract from gathering shares on the cheap. You and I both know the next run is gearing up and is coming.....you have picked up additional shares recently and I am playing the Bear Raid and sell the news mentality.

This is why you pick up shares below .35.....yes indeed the RUN is coming and we both know it!! $$$$$
Quote:
1) Pursuant to the terms and conditions of the Modified 135 Ludlow Lease, the Company is permitted to use the entire 35,000 square feet in the building located at 135-137 Ludlow Avenue for the storage of pharmaceutical finished goods, raw materials, equipment and documents as well as engaging in manufacturing, packaging and distribution activities.

Prior to the Modified 135 Ludlow Lease, the Company occupied only 15,000 square feet at the 135 Ludlow location. The Modified 135 Ludlow Lease accordingly represents a significant expansion in the size of the Northvale Facility.

2) Research and development costs for the three months ended June 30, 2014 were $4,020k, an increase of $3,451k or approximately 607% from $238k of such costs for the comparable period of the prior year. The increase was primarily due to increased activities related to the development of Elite’s abuse resistant opioid products.

3) The Company believes that the successful resolution of the monetary bond defaults will have a significant and positive effect on the Company’s operations.

Yes that does sound quite familiar. Good thing I listened to my gut just like I am now.

No more going concern, bond debt issue gone, partnership talks underway, NDA on track to be filed by years end....
Yeah just like ELTP was no good at .125 and the Mountain of cries for selling came and went like a hill of manure.
LMAO "If they exist at all" ....thats a good one.....so what is going to be said when Isradipine is launched??? Heard the same misinformation when the stock was at .06 and Elite was waiting on Methadone to launch.

Problem is all the antihype is being left in the dust. No more going concern and clearing up the bond debt issue.
Quote:
The significant increase in revenues is due to the continued growth and expansion of Elite’s generic product lines

Please do tell. What is happening on all the opioids besides being acclaimed into the pipeline. Yes I know, they are just in the pipeline.
Noticed that the revenue clip was removed and probably for good reason. There is not much there compared to the expenditures and we don't want to call attention to that. We also didn't mention the potential of additional dilution to pay for the dream 20,000sf addition that is designed to produce the 11 ANDAs that Epic will be doing for the substantial cut nor does it say what the current facilities, intended to take care of generics and ART, will be dedicated to. Oh don't say, they will continue producing the 8 generics.
Oh! Is there doubt? Should there be after all CEO said so! CEO said $5.00 then it must be $5.00.
Maybe two years ago they were considered good hype drugs if they exist at all.
Simple math
Attend Rodman Renshaw for confirmation. I think the price has gone up since last year. Or ask at the CC what % of pain market they expect to take .
You are correct. He stated he would look into why the two drugs awaiting FDA approval are undisclosed. Maybe we learn what they are. We also know from a CC about 2 years ago that they were considered "base hits" so neither considered major revenue generators.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 65

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 40

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 33

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
Peñoles Locks In Solar Storage for Northern Mine Loads

Updated Category News Views 159

A mine never sleeps, which is why the battery matters more than the solar-panel headline. Peñoles has signed a 20-year power-supply agreement with Atlas Renewable Energy for a Coahuila project combining 269 MWp of solar generation with battery storage. The project is slated to begin operating in the first half of 2029 and is expected to provide roughly 550 GWh a year to...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 47

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 23

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 116

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 95

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 77

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading

Top 5 Most Recently Viewed Articles

Elisa and Sensofusion Launch Joint Drone Venture in Europe

Updated Category News Views 293

A Match Made Beneath the Clouds Woke up today thinking about the bizarre world of drones, and it looks like Elisa Corporation and Sensofusion Plc are paving a new path in the skies of Europe. The two firms have locked hands to form Masthead Oy, aimed at creating a bird’s-eye defense mechanism to manage the unruly swarm of drones buzzing around Finland and Estonia. The...

Continue Reading
Innovative Alfapump Use in Elective Hernia Repair Highlights Benefits

Updated Category News Views 191

Innovative Solutions for Managing Ascites Managing ascites is vital, especially for patients encountering surgical options. Ascites, characterized by the accumulation of fluid in the abdomen, often complicates surgical procedures like umbilical hernia repairs. A significant number, about 20%, of individuals suffering from ascites due to liver cirrhosis are affected by...

Continue Reading
Kibu Unveils Insightful Cybersecurity Threat Report Series

Updated Category News Views 152

Kibu Unveils New Cybersecurity Threat Report Series Today, Kibu has announced the launch of an insightful quarterly threat report series that focuses on emerging challenges in the realm of cybersecurity. This new initiative aims to provide security teams with valuable insights derived from real-world scenarios and case studies, fully equipping them to tackle the evolving...

Continue Reading
Baidu Faces Securities Fraud Lawsuit: Key Investor Alert

Updated Category News Views 99

Stormy Weather for Baidu Investors Digging through the latest on Baidu's (NASDAQ:BIDU) unsettling journey feels like watching a rerun of a soap opera you wish would just end. The company has been slapped with a class action lawsuit by The Law Offices of Frank R. Cruz, accusing them of pulling the wool over investors' eyes from November 18, 2025, to August 17, 2026....

Continue Reading
Forecasting Earnings: What to Expect from IGC Pharma

Updated Category News Views 133

IGC Pharma's Approaching Earnings Announcement IGC Pharma (AMEX: IGC) is poised to disclose its quarterly earnings soon. Investors are looking forward to understanding the company's financial health and how it positions itself for the future. In the lead-up, it's vital to grasp the expectations that analysts have set. Analyst Estimates and Earnings Predictions Experts in...

Continue Reading